Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1220 results
June 2017
-
Media Release
FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®
FDA accepts Sandoz ANDA for substitutable generic version of Advair Diskus® Sandoz believes its combination product will offer asthma and COPD patients same safety and efficacy as reference… -
Media Release
Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
Cosentyx® is the first and only IL-17A inhibitor to show sustained improvements in signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA)[1],[2] Additional data… -
Media Release
Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
Data from the comprehensive clinical program show AMG 334 (erenumab) is safe and effective at preventing migraine in patients with 4 or more migraine days per month AMG 334 (erenumab)… -
Media Release
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff Best ORR was 59%, with 43%… -
Media Release
Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label
Tasigna is the first and only tyrosine kinase inhibitor (TKI) to include information on stopping therapy in Ph+ CML-CP patients in the EU product information Approval based on Novartis trials… -
Media Release
Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
Phase I/II study to evaluate Mekinist® (trametinib) in combination with Opdivo® (nivolumab) and Opdivo + Yervoy® (ipilimumab) Collaboration expands upon existing clinical investigation of… -
Media Release
Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer
Collaboration will use real-world patient data and cognitive computing with aim of improving outcomes in advanced breast cancer Brings Novartis innovation and breast cancer expertise together with… -
Media Release
Novartis landmark study of Tafinlar® + Mekinist® demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma
Study is longest follow-up to date of a BRAF and MEK inhibitor combination therapy in patients with BRAF V600-mutant metastatic melanoma[1] Study shows stable overall survival and progression-free… -
Media Release
Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
At a subsequent analysis of the MONALEESA-2 trial, after nearly one year of additional follow-up, Kisqali plus letrozole demonstrated median progression-free survival (PFS) of 25.3 months compared…
May 2017
-
Media Release
Progress reported in global fight against diarrheal disease cryptosporidiosis
Novartis, the University of Georgia, Washington State University and collaborators advance therapeutic research for cryptosporidiosis Research collaboration with novel drug discovery process… -
Media Release
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira®* and Remicade®** Comprehensive data… -
Media Release
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020 Focused and taking steps to become…